Trials / Recruiting
RecruitingNCT07035249
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
A Prospective, Single-Arm Clinical Trial Evaluating DCSZ11 Combined With Standard-of-Care Therapy in Patients With Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of DCSZ11 in combination with standard therapy in patients with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low Dose DCSZ11 | Patients will receive DCSZ11 at 600 mg every three weeks (Q3W). |
| DRUG | Medium Dose DCSZ11 | Patients will receive DCSZ11 at 800 mg Q3W. |
| DRUG | High Dose DCSZ11 | Patients will receive DCSZ11 at 1200 mg Q3W. |
| DRUG | Standard Treatment | The available standard treatment for head and neck cancer patients. |
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2027-06-01
- Completion
- 2027-07-30
- First posted
- 2025-06-25
- Last updated
- 2026-03-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07035249. Inclusion in this directory is not an endorsement.